Sitagliptin and metformin combination
Original question
Sitagliptin and metformin combination. Drugbank reference
Summary
The combination of sitagliptin and metformin is a commonly used therapeutic approach for managing type 2 diabetes mellitus. Here are the key points regarding this combination:
- Indication: This combination is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus[1][2][3].
- Mechanism of Action: Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), leading to increased levels of incretin hormones like glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which in turn increase insulin synthesis and decrease glucagon release in a glucose-dependent manner. Metformin, on the other hand, decreases liver uptake of lactate, increases insulin sensitivity, and reduces hepatic glucose production[1][2][4].
- Clinical Efficacy: The combination of sitagliptin and metformin has been shown to significantly improve glycemic control compared to monotherapy with either drug. It reduces HbA1c levels and has a favorable safety profile, with a low incidence of hypoglycemia[5][3].
Pharmacology
Sitagliptin
- Sitagliptin is an oral DPP-4 inhibitor that improves glycemic control by inhibiting the inactivation of incretin hormones, thereby increasing active incretin and insulin levels and decreasing glucagon levels[1][5].
- It is 87% orally bioavailable and can be taken with or without food without affecting its pharmacokinetics[1].
Metformin
- Metformin is a biguanide antihyperglycemic agent that decreases liver glucose production, increases insulin sensitivity, and enhances glucose uptake by muscles. It does not typically cause hypoglycemia when used alone[2][4].
Clinical Use
- The combination of sitagliptin and metformin is often used in patients with suboptimal glycemic control despite treatment with metformin alone. This combination has been shown to be noninferior to adding other antihyperglycemic agents like glipizide and has a favorable adverse event profile[5][3].
Safety and Tolerability
- The incidence of hypoglycemia with the sitagliptin and metformin combination is similar to that with placebo and lower than with glipizide when added to metformin. This combination generally has a neutral effect on body weight[5].
- Metformin carries a risk of lactic acidosis, although this is rare. Monitoring for signs of lactic acidosis, such as malaise, myalgias, and increased somnolence, is important[2].
Sources
- [DrugBank: Sitagliptin][1] https://go.drugbank.com/drugs/DB01261
- [DrugBank: Sitagliptin Article][5] https://go.drugbank.com/articles/A11454
- [DrugBank: Metformin][2] https://go.drugbank.com/drugs/DB00331
- [DrugBank: Metformin and Sitagliptin Search Results][4] https://go.drugbank.com/unearth/q?query=sitagliptin+metformin&searcher=drugs
- [DrugBank: Metformin+Sitagliptin Indications][3] https://go.drugbank.com/indications/DBCOND0144859
AI-generated answer based on the cited sources. Check the sources before applying it.